Which has preferable earnings and valuation, MDWD or CLYM?

MediWound has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 10.77 -$23.88M -$2.26 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is MDWD or CLYM more profitable?

Climb Bio has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Climb Bio's return on equity of -31.45% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -180.30% -67.22% -31.87% Climb Bio N/A -31.45% -30.39%

Which has better earnings & valuation, MDWD or CRMD?

CorMedix has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 10.77 -$23.88M -$2.26 N/A CorMedix $311.71M 2.20 $163.05M $2.13 4.10

Is MDWD or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to MediWound's net margin of -180.30%. CorMedix's return on equity of 45.57% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -180.30% -67.22% -31.87% CorMedix 45.25% 45.57% 24.76%

MediWound (MDWD) Competitors

$14.22 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$14.24 +0.02 (+0.14%)

As of 06/12/2026 04:39 PM Eastern

Compare

MDWD vs. SLDB, ANRO, ZVRA, CLYM, and CRMD

Should you buy MediWound stock or one of its competitors? MarketBeat compares MediWound with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediWound include Solid Biosciences (SLDB), Alto Neuroscience (ANRO), Zevra Therapeutics (ZVRA), Climb Bio (CLYM), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.

How does MediWound compare to Solid Biosciences?

MediWound (NASDAQ:MDWD) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

In the previous week, Solid Biosciences had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for MediWound. MediWound's average media sentiment score of 1.89 beat Solid Biosciences' score of 1.09 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Very Positive
Solid Biosciences	Positive

MediWound has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

MediWound currently has a consensus price target of $34.00, suggesting a potential upside of 139.10%. Solid Biosciences has a consensus price target of $17.00, suggesting a potential upside of 138.10%. Given MediWound's higher probable upside, analysts plainly believe MediWound is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Solid Biosciences has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Solid Biosciences	N/A	-73.42%	-61.13%

46.8% of MediWound shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MediWound has higher revenue and earnings than Solid Biosciences. MediWound is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.77	-$23.88M	-$2.26	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Summary

Solid Biosciences beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Alto Neuroscience has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Alto Neuroscience's return on equity of -47.22% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
MediWound	-180.30%	-67.22%	-31.87%

46.8% of MediWound shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alto Neuroscience has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, MediWound has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Alto Neuroscience presently has a consensus price target of $35.25, indicating a potential upside of 63.46%. MediWound has a consensus price target of $34.00, indicating a potential upside of 139.10%. Given MediWound's higher possible upside, analysts plainly believe MediWound is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

MediWound has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
MediWound	$16.96M	10.77	-$23.88M	-$2.26	N/A

In the previous week, Alto Neuroscience and Alto Neuroscience both had 1 articles in the media. MediWound's average media sentiment score of 1.89 beat Alto Neuroscience's score of 0.00 indicating that MediWound is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
MediWound	Very Positive

Summary

MediWound beats Alto Neuroscience on 8 of the 14 factors compared between the two stocks.

How does MediWound compare to Zevra Therapeutics?

MediWound (NASDAQ:MDWD) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

MediWound currently has a consensus target price of $34.00, indicating a potential upside of 139.10%. Zevra Therapeutics has a consensus target price of $29.29, indicating a potential upside of 131.51%. Given MediWound's higher possible upside, analysts clearly believe MediWound is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Zevra Therapeutics had 18 more articles in the media than MediWound. MarketBeat recorded 19 mentions for Zevra Therapeutics and 1 mentions for MediWound. MediWound's average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.15 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Very Positive
Zevra Therapeutics	Neutral

46.8% of MediWound shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MediWound has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.77	-$23.88M	-$2.26	N/A
Zevra Therapeutics	$106.47M	7.02	$83.23M	$1.99	6.36

Zevra Therapeutics has a net margin of 101.58% compared to MediWound's net margin of -180.30%. Zevra Therapeutics' return on equity of 51.49% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Zevra Therapeutics	101.58%	51.49%	28.86%

Summary

Zevra Therapeutics beats MediWound on 11 of the 16 factors compared between the two stocks.

How does MediWound compare to Climb Bio?

MediWound (NASDAQ:MDWD) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Climb Bio has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Climb Bio's return on equity of -31.45% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Climb Bio	N/A	-31.45%	-30.39%

MediWound presently has a consensus target price of $34.00, suggesting a potential upside of 139.10%. Climb Bio has a consensus target price of $21.73, suggesting a potential upside of 89.92%. Given MediWound's higher probable upside, equities analysts clearly believe MediWound is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

In the previous week, Climb Bio had 11 more articles in the media than MediWound. MarketBeat recorded 12 mentions for Climb Bio and 1 mentions for MediWound. MediWound's average media sentiment score of 1.89 beat Climb Bio's score of 0.43 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Very Positive
Climb Bio	Neutral

MediWound has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.77	-$23.88M	-$2.26	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

46.8% of MediWound shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MediWound has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Summary

Climb Bio beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to CorMedix?

MediWound (NASDAQ:MDWD) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, CorMedix had 4 more articles in the media than MediWound. MarketBeat recorded 5 mentions for CorMedix and 1 mentions for MediWound. MediWound's average media sentiment score of 1.89 beat CorMedix's score of 0.57 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Very Positive
CorMedix	Positive

MediWound presently has a consensus target price of $34.00, suggesting a potential upside of 139.10%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 71.62%. Given MediWound's higher possible upside, equities research analysts clearly believe MediWound is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

46.8% of MediWound shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 3.5% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CorMedix has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.77	-$23.88M	-$2.26	N/A
CorMedix	$311.71M	2.20	$163.05M	$2.13	4.10

MediWound has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

CorMedix has a net margin of 45.25% compared to MediWound's net margin of -180.30%. CorMedix's return on equity of 45.57% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
CorMedix	45.25%	45.57%	24.76%

Summary

CorMedix beats MediWound on 11 of the 16 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$182.73M	$2.99B	$6.53B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-6.29	18.84	23.99	24.42
Price / Sales	10.77	307.62	511.38	110.47
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	4.18	3.98	10.65	6.82
Net Income	-$23.88M	$75.79M	$3.57B	$337.56M
7 Day Performance	0.07%	1.57%	0.58%	1.17%
1 Month Performance	-13.35%	-0.73%	1.54%	3.16%
1 Year Performance	-30.36%	23.44%	25.40%	30.58%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	3.4685 of 5 stars	$14.22 flat	$34.00 +139.1%	-30.4%	$182.73M	$16.96M	N/A	80	Positive News
SLDB Solid Biosciences	2.7548 of 5 stars	$6.58 -8.5%	$16.36 +148.7%	+58.3%	$707.85M	N/A	N/A	100
ANRO Alto Neuroscience	1.8509 of 5 stars	$18.76 -5.3%	$35.25 +87.9%	+793.0%	$694.86M	N/A	N/A	N/A	News Coverage
ZVRA Zevra Therapeutics	4.3018 of 5 stars	$10.88 -5.3%	$23.33 +114.5%	+38.6%	$679.23M	$106.47M	5.47	20
CLYM Climb Bio	3.7388 of 5 stars	$11.20 -5.1%	$20.30 +81.3%	+807.9%	$675.70M	N/A	N/A	9	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors

MDWD vs. SLDB, ANRO, ZVRA, CLYM, and CRMD

How does MediWound compare to Solid Biosciences?

Summary

How does MediWound compare to Alto Neuroscience?

Summary

How does MediWound compare to Zevra Therapeutics?

Summary

How does MediWound compare to Climb Bio?

Summary

How does MediWound compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediWound (MDWD) Competitors

MDWD vs. SLDB, ANRO, ZVRA, CLYM, and CRMD

How does MediWound compare to Solid Biosciences?

Does the media favor MDWD or SLDB?

Which has more volatility & risk, MDWD or SLDB?

Do analysts rate MDWD or SLDB?

Is MDWD or SLDB more profitable?

Do institutionals & insiders have more ownership in MDWD or SLDB?

Which has better earnings and valuation, MDWD or SLDB?

Summary

How does MediWound compare to Alto Neuroscience?

Is ANRO or MDWD more profitable?

Do institutionals & insiders believe in ANRO or MDWD?

Which has more volatility & risk, ANRO or MDWD?

Do analysts rate ANRO or MDWD?

Which has preferable valuation and earnings, ANRO or MDWD?

Does the media refer more to ANRO or MDWD?

Summary

How does MediWound compare to Zevra Therapeutics?

Do analysts prefer MDWD or ZVRA?

Does the media prefer MDWD or ZVRA?

Do insiders and institutionals have more ownership in MDWD or ZVRA?

Which has more risk and volatility, MDWD or ZVRA?

Which has better valuation & earnings, MDWD or ZVRA?

Is MDWD or ZVRA more profitable?

Summary

How does MediWound compare to Climb Bio?

Is MDWD or CLYM more profitable?

Do analysts prefer MDWD or CLYM?

Does the media prefer MDWD or CLYM?

Which has preferable earnings and valuation, MDWD or CLYM?

Do insiders & institutionals hold more shares of MDWD or CLYM?

Which has more risk & volatility, MDWD or CLYM?

Summary

How does MediWound compare to CorMedix?

Does the media prefer MDWD or CRMD?

Do analysts rate MDWD or CRMD?

Do institutionals & insiders hold more shares of MDWD or CRMD?

Which has better earnings & valuation, MDWD or CRMD?

Which has more risk and volatility, MDWD or CRMD?

Is MDWD or CRMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools